Fact-checked by Grok 2 weeks ago

QT interval

The QT interval is a key component of the electrocardiogram (ECG) that represents the duration of ventricular electrical systole, encompassing the phases of ventricular depolarization and from the onset of the to the end of the . Physiologically, it corresponds to the ventricular duration, providing insight into the heart's process and overall electrical stability. Abnormalities in the QT interval, particularly prolongation or shortening, are associated with an increased risk of malignant ventricular arrhythmias, such as and sudden cardiac death. The QT interval varies with and is corrected (QTc) to a standardized value for assessment. Normal QTc values depend on age and gender, generally less than 440 milliseconds (ms) in adult males and less than 460 ms in adult females, though values can be longer in children and post-menopausal women. Prolongation is typically defined as exceeding 450 ms in males or 470 ms in females. Clinically, the QT interval holds significant implications for diagnosing and managing cardiac conditions, including congenital (LQTS), which arises from genetic defects, and acquired forms triggered by medications, imbalances, or structural heart disease. Prolonged QTc intervals, especially above 500 ms, markedly elevate the risk of polymorphic ; clinical management may include beta-blockers, implantable cardioverter-defibrillators, or avoidance of QT-prolonging drugs, while regulatory guidelines emphasize monitoring and evaluation in to mitigate proarrhythmic risks. A short QT interval is rarer and linked to (QTc ≤ 340 ms), predisposing to atrial and . Monitoring the QT interval is thus integral to routine ECG interpretation, risk stratification, and therapeutic decision-making in .

Definition and Physiology

Definition

The QT interval is measured on a surface electrocardiogram (ECG) as the duration from the beginning of the to the end of the . This interval encompasses the electrical activity associated with ventricular and . Specifically, it represents the total time for the ventricles to depolarize, as seen in the , followed by , which includes the and . In contrast to the , which captures only the rapid ventricular phase, the QT interval provides a broader view by incorporating the entire process. The , a component within the QT interval, spans from the end of the to the start of the and reflects the initial plateau of . The QT interval was first described in 1895 by , who named the key deflections P, Q, R, S, and T in his early ECG studies. He later developed the string galvanometer around 1901. Physiologically, it corresponds to the duration of the ventricular .

Physiological Role

The QT interval represents the temporal span of ventricular myocardial depolarization and repolarization, directly mirroring phases 0 through 3 of the action potential in ventricular myocytes. Phase 0 initiates rapid depolarization via influx of sodium ions through voltage-gated sodium channels, establishing the upstroke of the action potential. This is followed by phase 1, an early repolarization notch driven by transient outward potassium currents (I_to), and phase 2, the plateau phase, where a delicate balance between inward L-type calcium currents (I_Ca,L) and outward potassium currents sustains membrane depolarization to allow sufficient time for excitation-contraction coupling. Phase 3 then culminates in full repolarization, primarily through activation of delayed rectifier potassium currents that efflux potassium ions to restore the negative resting potential. Central to phase 3 are the rapid delayed rectifier (I_Kr), mediated by channels (KCNH2 gene), and the slow delayed rectifier (I_Ks), mediated by KCNQ1/KCNE1 channels, which together increase permeability to drive membrane hyperpolarization. Sodium currents, particularly the late sodium (I_Na,L), and calcium currents (I_Ca,L) indirectly regulate repolarization duration by prolonging the plateau if unopposed, while their inactivation supports the transition to phase 3. These ion channels form a redundant system known as repolarization reserve, where I_Ks activation compensates for potential reductions in I_Kr, ensuring robust even under stress. The exerts dynamic control over QT duration to adapt to physiological demands. Sympathetic stimulation, via beta-adrenergic pathways, enhances I_Ks conductance, shortening the action potential and QT interval to accommodate faster s during exercise or , thereby preventing excessive prolongation. In contrast, parasympathetic ( tends to prolong the QT interval by slowing and modulating expression, though its direct effects on currents are less pronounced. This bidirectional modulation ensures QT adaptation to variations, maintaining electrical stability and minimizing the risk of arrhythmias by preserving homogeneous across the ventricle. The adaptive significance of QT interval regulation lies in its role as a safeguard against arrhythmogenic heterogeneity during fluctuating cardiac workloads. By providing reserve through overlapping potassium currents, the system prevents duration prolongation at higher heart rates, which could otherwise foster early afterdepolarizations or re-entrant circuits. This physiological flexibility is evolutionarily conserved to support survival in environments requiring rapid cardiovascular adjustments, optimizing ventricular filling and contractility while averting life-threatening rhythm disturbances.

Assessment

Normal Values

The uncorrected QT interval in healthy typically ranges from 300 to 440 milliseconds, though this value decreases as increases due to its inherent dependence on length. The heart rate-corrected QTc interval provides a standardized measure, with normal values generally ≤440 milliseconds in adult males and ≤460 milliseconds in adult females. In pediatric populations, QTc values are similar to adults but exhibit variations; for instance, newborns may have upper limits up to 440 milliseconds in the first week of life, with mean values around 400 milliseconds, and intervals can transiently reach 500 milliseconds in the initial days before normalizing. Several factors influence these normal ranges. Age-related changes include slight prolongation of QTc with advancing years, such as thresholds increasing to 455 milliseconds for males and 460 milliseconds for females over 70 years. differences emerge post-puberty, with females exhibiting longer QTc intervals than males by approximately 10-20 milliseconds, attributed to hormonal influences. Racial variations also exist; for example, QT intervals tend to be shorter in Asian males but longer in Asian females compared to White counterparts, while may show shorter QTc overall. Borderline QTc values, indicating potential concern but not definitive abnormality, are often considered 431-450 milliseconds in adult males and 451-470 milliseconds in adult females, with prolongation defined as >450 milliseconds in males and >470 milliseconds in females in some age-stratified guidelines. These thresholds underscore the need for correction to accurately interpret QT intervals across diverse populations.

Measurement Methods

The QT interval is typically measured from a standard 12-lead electrocardiogram (ECG), with lead selection playing a critical role in accuracy. Lead II is commonly preferred due to its clear depiction of the , while precordial leads such as V5 or V6 serve as alternatives when they provide a more distinct T-wave . In cases where variability exists across leads, the lead yielding the longest QT interval should be selected to capture the maximum duration, and automated 12-lead analysis can integrate measurements from multiple leads for a global assessment. Manual measurement remains the gold standard for QT interval assessment, often employing digital calipers on ECG tracings to mark the onset of the and the end of the . Two primary techniques are used: the threshold method, which defines the T-wave end at its intersection with the (typically at 0 mV), and the tangent method, which draws a tangent line to the steepest downslope of the and identifies the intersection with the . The tangent method generally yields shorter QT intervals compared to the threshold method, with studies showing differences of up to 10-20 ms, but it exhibits lower inter-observer variability, making it preferable in clinical settings for reproducibility. For noisy signals or irregular rhythms, manual techniques may involve averaging multiple beats or using a superimposed beat to enhance signal clarity before measurement. Automated measurement, facilitated by ECG software algorithms, offers efficiency in high-volume settings but requires validation against manual methods due to potential inaccuracies in T-wave detection. These systems typically apply digital filters and pattern recognition to identify QRS onset and T-wave offset, often defaulting to the tangent or threshold approach, though discrepancies arise in up to 20% of cases compared to manual readings. Manual verification is recommended, particularly in scenarios with borderline values, as automated tools can overestimate or underestimate by 5-15 ms in the presence of artifacts. Several challenges complicate accurate QT measurement, including the distinction between T and U waves, where prominent U waves may be erroneously included, leading to QT prolongation artifacts of 20-50 ms. Variations in T-wave morphology, such as biphasic or notched patterns, further obscure the endpoint, necessitating careful visual inspection to exclude U-wave contributions and include the entire T-wave deflection. In atrial fibrillation, irregular R-R intervals introduce beat-to-beat variability, often requiring measurement from multiple cycles and averaging to mitigate errors exceeding 30 ms.

Heart Rate Correction Methods

The QT interval varies inversely with heart rate, shortening during faster rates due to a reduced RR interval and lengthening during slower rates, which complicates direct comparisons across individuals or within the same individual under varying physiological conditions. This variability arises because the QT interval reflects ventricular duration, which adapts dynamically to changes in length, but without adjustment, it cannot reliably indicate abnormalities like prolonged repolarization that increase the risk of arrhythmias such as . Heart rate correction standardizes the QT interval (QTc) to a reference , typically 60 beats per minute, enabling consistent clinical assessment independent of rate fluctuations. The RR interval, defined as the time in seconds between two consecutive R waves on the electrocardiogram, quantifies and forms the basis for all correction methods, as it inversely correlates with heart rate (shorter RR indicates faster rate). Correction approaches generally fall into linear and nonlinear categories, reflecting the debated nature of the QT-RR relationship. Linear methods, such as the Framingham formula derived from population-based , apply a straightforward proportional adjustment to the QT interval based on deviations from a reference RR, providing simplicity and reduced bias across moderate heart rates. In contrast, nonlinear methods, including those using or cubic root transformations of the RR interval (as in Bazett's or Fridericia's formulas), model the curvilinear dependency observed in physiological data, aiming to better capture adaptation at varying rates. Despite these approaches, heart rate correction methods have inherent limitations, particularly at extreme heart rates below 60 beats per minute or above 100 beats per minute, where over-correction (exaggerating QTc prolongation) or under-correction (masking true prolongation) commonly occurs, potentially leading to misdiagnosis of repolarization disorders. This stems from the dynamic, hysteresis-laden QT-RR relationship, where QT adaptation lags behind rate changes and varies individually due to autonomic influences, underscoring the need for context-specific formula selection.

Correction Formulas

Bazett's Formula

Bazett's formula, introduced by Henry C. Bazett in , calculates the corrected QT interval (QTc) to standardize the QT duration for a heart rate of 60 beats per minute. The formula is expressed as: \text{QTc} = \frac{\text{QT}}{\sqrt{\text{RR}}} where QT is the measured QT interval and RR is the interval between consecutive R waves, both in seconds. This correction assumes a parabolic relationship between the QT interval and the cardiac cycle length (RR interval), derived empirically from electrocardiographic data collected from 39 healthy men. Bazett adapted earlier work on systolic duration by Waller, fitting the data to a square-root model to account for the observation that QT duration shortens nonlinearly as heart rate increases. The formula's primary advantages lie in its mathematical simplicity and ease of manual calculation, making it the most widely used heart rate correction method in clinical settings, electrocardiogram reporting software, and major guidelines, including those from the . It facilitates rapid assessment of QT prolongation risk in routine practice without requiring complex computations. Despite its prevalence, Bazett's formula has notable limitations, particularly in its rate-correction accuracy outside moderate s. It overcorrects (overestimates QTc) at elevated heart rates greater than 100 beats per minute and undercorrects (underestimates QTc) at bradycardic rates below 60 beats per minute, leading to potential misclassification of QT abnormalities. For example, consider a with a measured QT of 0.30 seconds (300 ms) and RR of 0.50 seconds ( 120 ); applying the formula yields QTc = 0.30 / √0.50 ≈ 0.30 / 0.707 ≈ 0.424 seconds (424 ms), which overestimates the true corrected value relative to more linear formulas, potentially flagging unnecessary concern for prolongation. Conversely, for a QT of 0.40 seconds (400 ms) and RR of 1.00 seconds ( 60 , but illustrating low-rate bias in slower contexts), the formula gives QTc = 0.40 / √1.00 = 0.40 seconds (400 ms), but at even lower rates like RR = 1.20 seconds (50 ) with QT = 0.42 seconds, QTc ≈ 0.42 / √1.20 ≈ 0.42 / 1.095 ≈ 0.384 seconds (384 ms), underestimating by approximately 10-15 ms compared to individualized corrections. These biases arise from the formula's fixed square-root exponent, which does not fully capture the variable QT-RR across extreme rates.

Fridericia's Formula

Fridericia's formula for correcting the QT interval for was developed by Danish Louis Sigurd Fridericia in , based on electrocardiographic studies of 50 healthy individuals aged 16 to 82 years. Observing that the QT interval's duration varies inversely with but not in a simple linear fashion, Fridericia analyzed the relationship between the QT interval and the RR interval using mathematical modeling, including a two-constant equation to minimize measurement errors and achieve an average error of 0.015 seconds. He determined that the of the RR interval provided a more of this relationship compared to other exponents, leading to the formula's core structure. The formula is expressed as: \mathrm{QTc} = \frac{\mathrm{QT}}{\sqrt{{grok:render&&&type=render_inline_citation&&&citation_id=3&&&citation_type=wikipedia}}{\mathrm{RR}}} where and are measured in seconds, and QTc represents the corrected QT interval standardized to a of 60 beats per minute (RR = 1 second). This cubic root correction assumes a power-law that better captures the physiological shortening of ventricular at higher s. One key advantage of Fridericia's formula is its reduced tendency to overcorrect or undercorrect the QT interval at heart rate extremes relative to other methods, resulting in lower residual dependence on heart rate and improved prognostic accuracy in clinical populations. For instance, in a large , it demonstrated superior rate correction and better prediction of mortality outcomes compared to alternatives. It is also recommended by the U.S. for evaluating QT prolongation in certain drug safety trials, where precise heart rate adjustments are critical. Despite these strengths, Fridericia's formula is not ideal for very low heart rates, where it can still introduce some overestimation of QTc due to its exponential nature. To illustrate differences, consider a bradycardic example with RR = 1.5 seconds (heart rate ≈ 40 ) and measured QT = 0.48 seconds: Fridericia yields QTc ≈ 0.419 seconds (0.48 / 1.5^{1/3}, where 1.5^{1/3} ≈ 1.145), while a square-root method undercorrects to ≈ 0.392 seconds, potentially masking prolongation. In tachycardia ( = 0.5 seconds, = 120 , QT = 0.30 seconds), Fridericia gives QTc ≈ 0.378 seconds (0.30 / 0.5^{1/3}, where 0.5^{1/3} ≈ 0.794), avoiding excessive overcorrection seen in other approaches. These examples highlight its relative accuracy but underscore the need for context-specific application at extremes.

Other Formulas

In addition to the more commonly used nonlinear correction methods, several linear formulas have been developed to adjust the QT interval for heart rate, offering advantages in specific clinical contexts. The , derived from the longitudinal , provides a linear correction expressed as QTc = QT + 0.154(1 - RR), where QT and RR intervals are in seconds. This approach was proposed by Sagie et al. in 1992 as an improvement over earlier methods, emphasizing its suitability for population-based analyses due to reduced bias across a wide range of heart rates in large cohorts. Another linear correction is the Hodges formula, formulated as QTc = QT + 1.75(HR - 60), where QT is in milliseconds and HR is heart rate in beats per minute. Developed by Hodges in 1983, this method argues for a direct proportional relationship between QT interval and heart rate, avoiding the overcorrection seen in nonlinear formulas at extreme rates. These linear formulas, such as Framingham and Hodges, are particularly applicable in scenarios where nonlinear corrections like Bazett's or Fridericia's may introduce inaccuracies, including pediatric populations with higher baseline heart rates and athletic individuals during exercise-induced tachycardia. In population studies, the Framingham formula excels by maintaining stability across diverse heart rates without the rate-dependent distortions observed in other methods.

Formula Comparisons and Limitations

Various studies have compared the accuracy of QT correction formulas, with Fridericia's formula generally outperforming Bazett's across a wide range of heart rates. In a 2023 systematic review of athletes and young people, Fridericia's correction demonstrated the lowest heart rate dependence and highest accuracy for heart rates between 39 and 120 bpm, while Bazett's was least reliable outside 60-90 bpm, overestimating QTc at higher rates and underestimating at lower ones. Similarly, a 2016 analysis in a large cohort found Fridericia and Framingham formulas provided the best rate correction, with Bazett performing worst due to excessive variability at extremes of heart rate. Meta-analyses and cohort studies highlight significant variability in corrected QT (QTc) values across formulas, often resulting in differences of 20-30 ms that can affect clinical interpretation. For instance, upper limits of normal QTc using Bazett reached 472 ms in men and 482 ms in women, compared to approximately 450 ms with Fridericia, illustrating how formula choice influences threshold assessments. Short-term and long-term QTc stability analyses show Bazett introduces greater variability (standard deviation up to 12 ms) than Fridericia (around 6 ms), particularly during heart rate fluctuations. Recent research as of 2025 continues to support Fridericia's formula as the most accurate for correction in large healthy volunteer cohorts, with a 2025 of over 22,000 individuals confirming its minimal bias across broad ranges. Emerging methods aim to address remaining limitations; for example, the AccuQT approach, a model-free technique using to minimize information transfer between and QT intervals, has shown superior discrimination in patients and potential for clinical studies (as of 2024). Additionally, a demography-based adaptive formula (QTcAd), incorporating factors like age, demonstrated enhanced performance across pediatric and adult datasets in humans and animal models, published in February 2025. These developments suggest ongoing refinement, particularly for specialized populations. All QT correction formulas serve as approximations of the QT-RR relationship and carry inherent limitations, including reduced accuracy in the presence of arrhythmias or imbalances. Bazett and Fridericia both falter with R-R interval variability, such as in or , where irregular s distort corrections. None adequately account for direct influences of electrolytes like or hypomagnesemia on , potentially leading to erroneous QTc estimates independent of heart rate. ECG guidelines emphasize verifying QTc with multiple formulas in ambiguous cases to mitigate these limitations. The 2023 Canadian Cardiovascular Society guidelines favor Bazett for routine use but highlight its inaccuracies at heart rates below 60 bpm or above 100 bpm, recommending manual measurement and consideration of alternatives like Fridericia for faster rates to ensure reliable assessment. Regulatory bodies such as the FDA and endorse Fridericia for drug safety studies, underscoring the need for formula selection based on clinical to improve verification.

Abnormal Intervals

Prolonged QT Interval

The QT interval is considered prolonged when the heart rate-corrected QT interval (QTc) exceeds milliseconds (ms) in males or 460 ms in females, based on standard electrocardiographic criteria for identifying abnormalities. Degrees of prolongation are often classified as mild (451-500 ms) or severe (>500 ms), with severe cases carrying heightened clinical concern due to risk. These thresholds account for sex-based differences in duration, where females typically exhibit longer baseline QTc values post-puberty. On electrocardiogram (ECG), prolonged QT intervals manifest with characteristic repolarization changes, including flattened or low-amplitude s, notched s (particularly in leads V2-V3), and prominent U waves that may fuse with the , complicating measurement. These features reflect delayed ventricular and are more pronounced in severe prolongation, often requiring measurement in multiple leads (e.g., , V5) for accuracy. Prolonged QT intervals increase susceptibility to early afterdepolarizations (EADs), triggered by prolonged duration that reactivates L-type calcium channels during phase 3 of the . EADs can initiate polymorphic , such as , potentially degenerating into and sudden cardiac death. In the general , prolonged QTc affects approximately 2-5% of individuals in Western populations, with higher (up to 15%) reported in some Asian cohorts; overall, it is more common in females, older adults, and those with comorbidities such as imbalances or cardiac disease. Congenital forms, due to genetic mutations, occur in about 1 in 2,000 people but represent only a of cases.

Short QT Interval

A short QT interval is generally defined as a corrected QT interval (QTc) of less than 360 milliseconds in adults, though thresholds can vary slightly by sex and measurement method, with values below 330-350 ms often indicating a more severe abnormality associated with (SQTS). SQTS represents a rare inherited arrhythmogenic disorder characterized by accelerated cardiac , leading to this abbreviated QT duration, and is typically diagnosed when the short QT is accompanied by symptoms such as syncope or family history of sudden cardiac events. On electrocardiogram (ECG), a short QT interval in SQTS often manifests with distinctive features, including tall and peaked s, particularly in the precordial leads, and a shortened or absent , where the appears to rise immediately after the . These morphological changes reflect the underlying dysfunction that hastens ventricular , distinguishing it from other causes of abbreviated QT such as hypercalcemia or effects. The clinical risks associated with a short QT interval include a heightened susceptibility to life-threatening arrhythmias, notably ventricular fibrillation (VF) and atrial fibrillation (AF), which can precipitate sudden cardiac arrest, particularly in younger individuals. SQTS has a low prevalence, estimated at 0.02% to 0.1% in the general population, making it an underrecognized entity compared to its counterpart, long QT syndrome. Recent analyses from 2025 have highlighted a U-shaped relationship between QTc duration and adverse outcomes, showing that short QTc intervals (below approximately 350 ms) are linked to increased 3-month risks of new-onset AF, ventricular arrhythmias, and all-cause mortality, independent of other cardiovascular factors.

Causes of Abnormalities

Genetic Causes

Genetic causes of QT interval abnormalities primarily involve inherited channelopathies affecting cardiac channels, leading to either prolongation or shortening of the QT interval. The most common is (LQTS), an autosomal dominant disorder characterized by delayed ventricular repolarization due to loss-of-function mutations in or genes. LQTS types 1 through 3 account for the majority of cases, with mutations in KCNQ1 (LQT1, 30%-35% of cases) causing reduced IKs current, KCNH2 (LQT2, 25%-30%) impairing IKr, and (LQT3, 5%-10%) resulting in persistent sodium influx. These mutations lead to heterogeneous T-wave morphologies and triggers specific to each subtype, such as exercise for LQT1 and auditory stimuli for LQT2. The prevalence of congenital LQTS is estimated at 1:2000 live births. Romano-Ward syndrome represents the autosomal dominant form of LQTS without congenital deafness, distinguishing it from the recessive Jervell and Lange-Nielsen syndrome. It is caused by heterozygous mutations in the same major genes (KCNQ1, KCNH2, SCN5A), which disrupt ion channel function and prolong the action potential duration. LQTS exhibits incomplete penetrance, with approximately 25% of mutation carriers displaying a normal QTc interval (<440 ms), and variable expressivity, where clinical severity ranges from asymptomatic to sudden cardiac death, influenced by genetic modifiers and environmental factors. Short QT syndrome (SQTS), a rarer autosomal dominant condition, results from gain-of-function mutations that accelerate , shortening the QTc to <320 ms and increasing susceptibility to atrial and ventricular arrhythmias. Key subtypes include SQT1 due to KCNH2 mutations enhancing IKr, SQT2 from KCNQ1 variants boosting IKs, and SQT3 involving KCNJ2 increasing IK1; additional types (4-6) are linked to genes like CACNA1C and CACNB2 affecting calcium channels, though evidence for some remains moderate. Fewer than 200 families have been reported worldwide as of 2023, underscoring its rarity. The estimated prevalence is approximately 0.02% to 0.1% (2.7 per 100,000 individuals). Other genetic disorders impacting the QT interval include Andersen-Tawil syndrome (ATS), classified as LQT7, which features prolonged QTc or QUc intervals alongside and dysmorphic features due to KCNJ2 mutations that suppress inward rectifier potassium currents. These mutations exert a dominant-negative effect, altering and producing distinctive T-U wave patterns on ECG. Diagnosis of these genetic QT abnormalities relies on molecular genetic testing, which identifies a pathogenic variant in approximately 80% of LQTS cases and is recommended for symptomatic individuals with QTc prolongation, family history of sudden death, or high clinical suspicion per 2024 international guidelines. Cascade screening of first-degree relatives is advised when a variant is confirmed in the proband, given the incomplete penetrance and variable expressivity that necessitate clinical correlation beyond genetic findings alone. Early testing in minors is supported for risk stratification and preventive measures.

Drug-Induced Causes

Drug-induced prolongation of the QT interval primarily occurs through blockade of the human ether-à-go-go-related gene (hERG) potassium channel, which encodes the rapid delayed rectifier current (I_Kr) responsible for cardiac repolarization. This blockade delays ventricular repolarization, extending the action potential duration and thereby prolonging the QT interval on the electrocardiogram (ECG). In addition to direct channel inhibition, some drugs disrupt hERG protein trafficking to the cell membrane, reducing functional channel availability and contributing to the same effect. Common examples include antiarrhythmic agents like sotalol, which potently blocks hERG and is associated with dose-dependent QT prolongation of 10-40 ms at therapeutic doses; macrolide antibiotics such as erythromycin, which inhibits I_Kr and poses a conditional risk; and antipsychotics like haloperidol, known for significant hERG affinity leading to marked QT extension in susceptible individuals. The CredibleMeds database categorizes QT-prolonging drugs based on their risk of (TdP), a potentially fatal ventricular linked to excessive QT prolongation. Drugs in the Known Risk (KR) category demonstrate strong evidence of causing TdP, such as and ; Possible Risk (PR) includes agents with documented QT prolongation but insufficient TdP evidence, exemplified by recent additions like mavorixafor in August 2024; and Conditional Risk (CR) covers drugs that prolong QT under specific circumstances, like imbalances or high doses, including erythromycin and new entries such as , revumenib, and sitafloxacin added in December 2024. Post-2023 updates reflect ongoing , with April 2024 reclassifying to KR due to TdP cases and adding quizartinib to KR, alongside December 2023 adjustments to several entries based on emerging clinical data. The incidence of drug-induced (LQTS) varies by agent and population but generally affects 1-3% of patients exposed to high-risk drugs, with TdP occurring at a rarer rate of approximately 4 cases per 100,000 person-years in hospitalized settings. Monitoring protocols recommend baseline ECG assessment prior to initiating with KR or PR drugs, especially in patients with risk factors like sex, advanced age, or , followed by repeat ECGs at peak drug levels or after 3-5 days for ongoing . If QTc exceeds 500 ms or increases by >60 ms from baseline, dose reduction, discontinuation, or electrolyte correction (e.g., , magnesium) is advised to mitigate TdP risk. Recent advances in 2024 include models like QTNet, a () applied to ECGs that predicts drug-induced LQTS with high accuracy in outpatient settings, outperforming traditional manual measurements by integrating waveform morphology and maintaining performance over time. Such tools enhance early detection, particularly for scenarios common in psychiatric and critical care patients.

Acquired Causes from Pathologies

Acquired causes of QT interval abnormalities arising from underlying pathologies encompass a range of non-genetic, non-pharmacological medical conditions that disrupt cardiac through mechanisms such as disturbances, hormonal imbalances, or ischemic processes. These pathologies can lead to either prolongation or shortening of the QT interval, increasing the risk of ventricular arrhythmias like . Electrolyte imbalances are among the most common acquired pathological causes of QT prolongation. , often resulting from conditions like gastrointestinal losses or renal disorders, reduces the outward potassium current (IKr), thereby extending the action potential duration and QT interval. Similarly, hypomagnesemia impairs by affecting potassium channels, while prolongs the ST segment, contributing to an extended QT interval; these imbalances are frequently observed in critically ill patients and can compound each other. In contrast, , typically from or , shortens the QT interval by accelerating phase 2 due to increased calcium influx. Various systemic diseases also induce QT abnormalities through direct myocardial effects or autonomic dysregulation. prolongs the QT interval by reducing thyroid hormone modulation of channels, leading to decreased repolarizing currents; this effect is reversible with thyroid replacement . Myocardial ischemia, as seen in acute coronary syndromes, causes heterogeneous prolongation due to regional and altered function, with QTc extension correlating to infarct size and adverse outcomes. , particularly ischemic types, is associated with QT prolongation in 38-71% of cases, likely from central autonomic imbalance and neurogenic stress, heightening risk. Additional pathological states include and , which both promote QT prolongation. In , such as in or severe , electrolyte shifts and extend the QT interval, often within normal ranges but predisposing to arrhythmias. slows kinetics, prolonging the QT interval and potentially inducing Osborn waves on ECG. These acquired abnormalities are prevalent in (ICU) settings, affecting up to 24-25% of patients due to multifactorial stressors like or organ failure. Recent studies as of 2025 highlight links between QT prolongation and specific chronic pathologies. In , QT interval extension occurs in up to 70% of cases, correlating with disease severity, imbalances, and complications like or , independent of cirrhotic cardiomyopathy. Among patients, particularly those with opportunistic infections such as or pneumocystis, QT prolongation is prevalent (up to 30-50%), driven by , immune dysregulation, and associated disturbances, elevating sudden cardiac death risk.

Clinical Significance

Associated Arrhythmias and Risks

Prolonged QT intervals are strongly associated with (TdP), a polymorphic that can degenerate into and sudden cardiac death. In patients with congenital (LQTS), TdP typically arises from early afterdepolarizations during . Short QT intervals, as seen in (SQTS), predispose individuals to (VF) due to accelerated and shortened periods, leading to re-entrant arrhythmias and a high risk of . SQTS is characterized by familial sudden death, with VF often inducible during electrophysiological studies. In LQTS type 2, events such as syncope and seizures are frequently triggered by pause-dependent mechanisms, such as sudden auditory stimuli or from sleep, which initiate short-long-short sequences promoting TdP. These symptoms, often misdiagnosed as , occur more commonly in LQT2 compared to other genotypes and can result from transient cerebral hypoperfusion during arrhythmic episodes. Recent analyses from 2025 highlight the short-term risks of QT extremes, showing a U-shaped relationship where both prolonged (>500 ms) and short (<370 ms) QTc intervals correlate with elevated 3-month hazards of new-onset atrial fibrillation (HR 7.4-7.7) and ventricular arrhythmias, independent of underlying genetic causes like LQTS or SQTS.

Prognostic Implications

The QT interval, particularly when corrected for heart rate (QTc), serves as a significant prognostic marker for mortality in general populations. Prolonged QTc intervals exceeding 440 ms have been associated with an increased risk (hazard ratios approximately 1.2- to 1.7-fold) of cardiovascular death, independent of other factors. For instance, in a large cohort study, individuals in the highest tertile of long-term average QTc demonstrated a 24% higher hazard ratio for all-cause mortality compared to those in the lowest tertile, after adjusting for demographics and comorbidities. Similarly, the has linked prolonged QTc to elevated all-cause mortality risk, with analyses confirming this association persists even when accounting for heart rate correction methods like . Short QTc intervals also carry prognostic weight, showing a U-shaped risk profile for mortality outcomes. Recent 2025 analyses from a retrospective cohort of over 145,000 patients revealed that short QTc (200–370 ms) was associated with a hazard ratio of 10.03 for 3-month all-cause mortality compared to normal ranges (370–420 ms), highlighting heightened immediate risks. This finding aligns with broader evidence that deviations in either direction from normal QTc values predict adverse events, though short QTc risks may be partially attenuated after excluding influences like QT-prolonging medications. QTc prolongation acts as an independent predictor of mortality beyond traditional factors, such as left ventricular . In post-myocardial patients, QTc >445 ms independently forecasted all-cause death and , adding prognostic value to clinical predictors like NT-proBNP. A validated score study further demonstrated that QT prolongation predicted all-cause mortality with a of 1.90 for short-term events, overriding indices like the Charlson score. However, limitations include by underlying comorbidities, which can influence QTc measurements and outcomes; for example, renal dysfunction or imbalances may exaggerate associations. Additionally, QT variability (QTV), an advanced metric capturing beat-to-beat fluctuations, offers enhanced prognostic insight, independently predicting 5-year mortality post-myocardial with risks up to 16% in high-QTV groups versus 4% in low-QTV groups among those with preserved .

Role in Specific Conditions

In , prolongation of the corrected QT interval (QTc) beyond 424 ms has been identified as a predictor of increased mortality, largely driven by the underlying inflammatory burden that exacerbates cardiovascular risk. This threshold, derived from median QTc values in cohort studies, highlights how chronic inflammation in contributes to abnormalities, thereby elevating the likelihood of adverse cardiac outcomes in affected patients. In type 1 diabetes, a QTc exceeding 440 ms is strongly associated with cardiac autonomic neuropathy, a condition that impairs vagal and sympathetic control of the heart, leading to heightened mortality risk. Longitudinal data indicate that such prolongation approximately doubles the risk of all-cause death in type 1 diabetic populations. Autonomic dysfunction further amplifies this by promoting heterogeneous repolarization, as evidenced in studies linking QT indices to arrhythmic events in type 1 diabetes patients. For , QT —measuring variability in QT intervals across leads—serves as a superior prognostic indicator compared to simple QTc prolongation alone, particularly for long-term cardiovascular mortality. In a 15-year follow-up of over 1,300 patients, elevated QT dispersion independently predicted cardiovascular death with a of 1.26, even after adjusting for confounders like age and , while QTc length showed no significant association. This metric better captures myocardial inhomogeneity driven by diabetic microvascular changes, offering enhanced predictive value in routine clinical assessment. In , QTc prolongation emerges as an independent risk factor for sudden cardiac death and all-cause mortality, with prevalence rising to over 60% in advanced stages. Uremic toxins and electrolyte derangements contribute to this abnormality, conferring a of up to 2.6 for mortality in cohorts with extended QTc, independent of dialysis status. Such changes portend poor prognosis, particularly in end-stage renal disease, where they correlate with heightened cardiovascular event rates. Among patients, chemotherapy-induced QT prolongation, often from agents like inhibitors or , heightens the risk of torsades de pointes and sudden cardiac death, complicating treatment regimens. Up to 40% of patients on certain therapies exhibit severe QTc extension (>500 ms), necessitating vigilant monitoring to mitigate fatal arrhythmias while preserving oncologic efficacy. The 2025 resurgence of pertussis has drawn attention to its underrecognized cardiac complications, including QT interval prolongation in severe pediatric cases, which may precipitate arrhythmias amid respiratory distress. In infants, this abnormality, alongside , contributes to acute hemodynamic instability, with early ECG evaluation recommended to avert life-threatening events during outbreaks.

Use in Drug Development and Approval

The assessment of QT interval prolongation plays a central role in to mitigate the risk of and other arrhythmias. The International Council for Harmonisation (ICH) E14 guideline, adopted in 2005, mandates the clinical evaluation of a drug's potential to prolong the QT/QTc interval through dedicated Thorough QT (TQT) studies, typically conducted early in clinical development during phase I trials to inform subsequent phases. These studies involve randomized, placebo- and positive-controlled designs to measure changes in QTc, with a of concern set at 5 milliseconds or more for regulatory purposes. An update to the E14 guideline via questions and answers in 2022, endorsed by regulatory bodies including the FDA, has refined implementation, emphasizing integrated assessments that have led to a 34% reduction in dedicated TQT studies between 2016 and 2024 by allowing alternatives for low-risk drugs. To streamline evaluations and reduce costs, newer strategies have shifted toward modeling and preclinical screening. Concentration-QTc (C-QTc) modeling analyzes the exposure-response relationship between drug plasma concentrations and QTc changes, often using data from early-phase trials to predict effects without a full TQT study, thereby reducing sample sizes and resource demands. Complementing this, preclinical assays targeting the human ether-à-go-go-related gene () channel, as outlined in ICH S7B guidelines, screen for blockade that may lead to delays, providing an early indicator of QT risk before advancing to clinical stages. Advancements in have further enhanced QT assessment efficiency. Between 2023 and 2025, (CNN) models have been developed to predict from ECG data, achieving high accuracy in outpatient settings and outperforming traditional methods for identifying risks. Similarly, mobile applications like the QTc Tracker app, introduced in 2023, support semi-automated QTc measurements using single-lead ECGs from smartphones, particularly aiding oncological to detect prolongation in routine . Regulatory outcomes from QT evaluations directly influence drug approval and post-market actions. The FDA requires labeling warnings for drugs with QT-prolonging potential, categorizing risks as conditional, known, or possible based on TQT and modeling results. In cases of significant risk, drugs may be withdrawn; for instance, terfenadine, an antihistamine associated with dose-dependent QT prolongation and torsades de pointes, was removed from the U.S. market in 1998 after safer alternatives emerged.

References

  1. [1]
    ECG series. Importance of QT interval in clinical practice - PMC - NIH
    QT interval represents the duration of ventricular electrical systole, which includes ventricular activation and recovery. It is measured from the beginning of ...
  2. [2]
    Long QT Syndrome - StatPearls - NCBI Bookshelf - NIH
    The QT interval on an electrocardiogram (ECG) represents the duration of the ventricular action potential, and this physiologically correlates with the ...
  3. [3]
    The Measurement of the QT Interval - PMC - PubMed Central - NIH
    The QT interval is measured from the beginning of the QRS complex to the end of the T-wave, and should be corrected for heart rate to enable comparison with ...
  4. [4]
    [PDF] FDA Guidance for Industry E14 Clinical Evaluation of QT/QTc ...
    Clinically noteworthy. QT/QTc interval changes might be defined in terms of absolute QT/QTc intervals or changes from baseline. Separate analyses should be ...
  5. [5]
    Short QT syndrome: MedlinePlus Genetics
    Jun 1, 2013 · In people with this condition, the part of the heartbeat known as the QT interval is abnormally short. If untreated, the arrhythmia associated ...
  6. [6]
    Long QT Syndrome (LQTS)
    The QT interval represents both ventricular depolarization and repolarization. The QT interval varies with heart rate. The faster the heart rate, the shorter ...
  7. [7]
    Conquering the ECG - Cardiology Explained - NCBI Bookshelf
    The ST segment, which is also known as the ST interval, is the time between the end of the QRS complex and the start of the T wave. It reflects the period of ...
  8. [8]
    ST Segment - StatPearls - NCBI Bookshelf - NIH
    The junction (J) point is where the QRS complex and ST segment meet. It marks the beginning of the ST segment. Any displacement of the ST segment above or below ...Missing: QT | Show results with:QT
  9. [9]
    QT Assessment in Early Drug Development: The Long and the Short ...
    History of The QT Interval and Its Importance in Early Drug Development. In 1895, Einthoven developed the human electrocardiogram (ECG) and described the PR ...
  10. [10]
    Non-Pacemaker Action Potentials - CV Physiology
    Atrial myocytes and ventricular myocytes are examples of non-pacemaker action potentials in the heart. Because these action potentials undergo very rapid ...<|control11|><|separator|>
  11. [11]
    Physiology, Cardiac Repolarization Dispersion and Reserve - NCBI
    Apr 17, 2023 · Thus IKs provide a repolarization reserve or a physiologic check to prevent excess action potential duration lengthening and QT prolongation.
  12. [12]
    Cardiac transmembrane ion channels and action potentials
    Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle. Circulation 112: 1392–1399, 2005. doi ...
  13. [13]
    Insights into Cardiac IKs (KCNQ1/KCNE1) Channels Regulation
    The cardiac IKs (KCNQ1/KCNE1) channel is one of the main contributors to the repolarizing currents that regulate the ventricular action potential duration (APD)
  14. [14]
    Modulation of QT Interval During Autonomic Nervous System ...
    Conclusions— Autonomic blockade prolongs QT interval in normal subjects to a similar duration as in PAF patients. Furthermore, blocking residual autonomic tone ...
  15. [15]
    Influence of autonomic tone on QT interval duration - PubMed
    The autonomic tone has been shown to influence the duration of the QT interval, however the independent contribution of sympathetic and parasympathetic tone ...
  16. [16]
    Diurnal variation of the QT interval--influence of the autonomic ...
    Diurnal changes of the QT interval may be pronounced in the innervated heart and are dependent on both variations in autonomic tone and concentrations of ...
  17. [17]
    Determination and Interpretation of the QT Interval | Circulation
    Aug 23, 2018 · A QTc interval >480–500 ms on repeated ECGs is considered diagnostic for LQTS, whereas a value >460–480 ms on repeated ECGs in the presence of ...Missing: uncorrected | Show results with:uncorrected
  18. [18]
    Prolongation of the QT Interval and the Sudden Infant Death Syndrome
    Jun 11, 1998 · For newborns, unlike adults, a QTc of 440 msec should be considered the upper limit of normal for both males and females. Prolongation of the QT ...
  19. [19]
    QTc Interval Reference Values & Maturational Factors in Neonates
    As the mean QTc intervals were 401 and 400 ms in male and female newborns, no significant differences were found between both sexes. This was confirmed by ...
  20. [20]
    New age- and sex-specific criteria for QT prolongation based on rate ...
    Jul 1, 2014 · The criteria established for prolonged QTc were: Age < 40 years, men 430 ms, women 440 ms; Age 40 to 69, men 440 ms, women 450 ms; Age ≥ 70 years, men 455
  21. [21]
    Sex differences in the mechanisms underlying long QT syndrome
    The diagnosis of LQTS is sex specific and defined as QTc > 440 ms for adult males and > 460 ms for adult females (12). LQTS is considered to be an electrical ...
  22. [22]
    Racial Differences in Electrocardiographic Characteristics and ...
    Mar 25, 2016 · The QT interval was shorter in Asian men but longer in Asian women compared with White men and women, respectively. These ECG differences were ...
  23. [23]
    [PDF] A Review of Racial Differences and Disparities in ECG
    Feb 25, 2025 · Differences in QT intervals across racial groups have been documented, with shorter QT intervals reported in African American and Asian.
  24. [24]
    How to: measure the QT interval? - European Society of Cardiology
    Mar 12, 2024 · QT measurement at this point in time should be done manually using either the tangent or threshold method in lead II or V5, using Bazett's formula to correct ...
  25. [25]
    QT Interval - ECG Library Basics - LITFL
    Oct 8, 2024 · Corrected QT interval (QTc) · Bazett formula: QTC = QT / √ RR · Fridericia formula: QTC = QT / RR · Framingham formula: QTC = QT + 0.154 (1 – RR) ...Drugs Causing QT Prolongation · Short QT Syndrome · Bazett formulaMissing: authoritative | Show results with:authoritative
  26. [26]
    AHA/ACCF/HRS Recommendations for the Standardization and ...
    Feb 19, 2009 · It is recommended that linear regression functions rather than the Bazett's formula be used for QT-rate correction and that the method used for ...
  27. [27]
    Manual vs. automatic assessment of the QT-interval and corrected QT
    Jul 20, 2023 · For automatic QTc results from 440–540 ms (tangent) and 430–530 ms (threshold), misassessment risk was highest. Novel automatic QT-interval ...Missing: source:
  28. [28]
    Automated versus Manual Measurement of the QT Interval and ... - NIH
    Apr 18, 2011 · With both automated and manual measurement, QT intervals obtained by the tangent method were shorter than those obtained by the differential ...
  29. [29]
    Measurement and Rate Correction of the QT Interval
    Jan 1, 2013 · Whenever more than a single lead is available, the lead with the longest QT interval should be selected for the QT interval measurement. ...
  30. [30]
    Comparison of QT Interval Measurement Methods and Correction ...
    Jun 1, 2019 · In the present study we aimed to determine which QT correction formula and method for interval measurement was best for determining QTc in AF.
  31. [31]
    What Clinicians Should Know About the QT Interval - JAMA Network
    The QT interval should be measured manually, preferably by using one of the limb leads that best shows the end of the T wave on a 12-lead ECG.
  32. [32]
    The fallacies of QT correction - PMC - NIH
    The purpose of heart rate correction is to obtain a standardized value that would have been measured in the same subject if the heart rate was 60 beats per ...Missing: rationale | Show results with:rationale<|separator|>
  33. [33]
    An improved method for adjusting the QT interval for heart rate (the ...
    The linear regression model yielded a correction formula (for a reference RR interval of 1 second): QTLC = QT + 0.154 (1 − RR) that applies for men and women.
  34. [34]
    Methods of Assessment and Clinical Relevance of QT Dynamics - NIH
    Jul 1, 2005 · Both linear and non-linear methods of assessment of QT dynamics have been described. Linear assessment of QT dynamics and its clinical relevance.
  35. [35]
    Bazett formula • LITFL • Medical Eponym Library
    Sep 4, 2025 · Historically, Bazett (1920) derived a formula based on the work of Waller (1891) defining an ideal QT for any individual at a given heart rate.Missing: paper | Show results with:paper<|control11|><|separator|>
  36. [36]
  37. [37]
    Influence of heart rate correction formulas on QTc interval stability
    Jul 12, 2021 · The study concludes that (a) previous suggestions that Bazett correction should no longer be used in clinical practice are fully justified.Missing: rationale | Show results with:rationale
  38. [38]
  39. [39]
    Which QT Correction Formulae to Use for QT Monitoring?
    Jun 17, 2016 · Fridericia and Framingham correction formulae showed the best rate correction and significantly improved prediction of 30-day and 1-year mortality.Methods · Results · Qtc/rr Analysis
  40. [40]
    Comparison of Formulas for Calculation of the Corrected QT Interval ...
    Although the Bazett formula is the most widely used correction method in clinical practice, the Fridericia formula is recommended by the U.S. Food and Drug ...Missing: authoritative sources
  41. [41]
    Using the appropriate formula for QT measurement can save lives
    Jun 21, 2021 · We recommend the adoption of the Fridericia or Framingham formulae for measurement of QTc in all cancer patients exposed to potentially QT-prolonging cancer ...
  42. [42]
    An improved method for adjusting the QT interval for heart ... - PubMed
    Several formulas have been proposed to adjust the QT interval for heart rate, the most commonly used being the QT correction formula (QTc = QT/square root ...
  43. [43]
    Comparison of Formulas for Calculation of the Corrected QT Interval ...
    To compare 4 heart rate correction formulas for calculation of the rate corrected QT (QTc) interval among infants and young children.
  44. [44]
    Comparison of methods for correcting QT interval in athletes and ...
    Jul 20, 2023 · The Bazett method of QT correction is less accurate at lower and higher HRs. Amongst other correction formulae, Fridericia has been shown to be ...
  45. [45]
    Influence of heart rate correction formulas on QTc interval stability
    Jul 12, 2021 · The results showed that (a) both in terms of short-term and long-term QTc variability, Bazett correction led to QTc values that were more ...Missing: meta- | Show results with:meta-
  46. [46]
  47. [47]
    QT heart rate correction by Bazett – we can do better! - Crediblemeds
    Oct 30, 2023 · Bazett recommended dividing the QT by the square root of the heart rate (measured as RR interval) and Fridericia recommended dividing QT by the ...Missing: rationale | Show results with:rationale
  48. [48]
    The QT Interval | Circulation - American Heart Association Journals
    Jun 10, 2019 · Until recently, the heart rate–corrected QT interval (QTc), which represents a dynamic measurement of the time required to reset the heart's ...Missing: rationale | Show results with:rationale
  49. [49]
    Acquired long QT syndrome: Definitions, pathophysiology, and causes
    Nov 21, 2024 · After puberty in males, a QTc between 460 and 469 is borderline and ≥470 is considered prolonged. In post-pubertal females, 460 to 479 is ...Missing: standard | Show results with:standard
  50. [50]
    Pause induced early afterdepolarizations in the long QT syndrome
    The long QT syndrome (LQTS) is a cardiac disorder characterized by marked prolongation of the QT interval. It often manifests clinically as syncope, seizures, ...Missing: risks | Show results with:risks
  51. [51]
    Long-QT Syndrome | Circulation: Arrhythmia and Electrophysiology
    Aug 1, 2012 · 1, generating IKs, which, being physiologically increased by sympathetic activation, is essential for QT adaptation when heart rate increases.Genetics Of Lqts · Major Lqts Genes · Current ManagementMissing: adaptive | Show results with:adaptive
  52. [52]
    Association of QTc Interval with Risk of Cardiovascular Diseases ...
    For example, the prevalence of QTc interval prolongation is below 5% among Americans [27, 28] but is up to 13.7% in Chinese [29], suggesting a higher presence ...
  53. [53]
    Congenital Long QT Syndrome | JACC: Clinical Electrophysiology
    The prevalence of LQTS is estimated to be ∼1:2,000, with a slight female predominance. The diagnosis of LQTS is based on clinical, electrocardiogram, and ...
  54. [54]
    Short QT Syndrome – Review of Diagnosis and Treatment - PMC - NIH
    Today, SQTS is usually defined as QTc ≤330 ms, or QTc interval <360 ms and one or more of the following: history of cardiac arrest or syncope, family history ...
  55. [55]
    Prevalence and Prognostic Significance of Short QT Interval in a ...
    Aug 6, 2007 · The cutoff values for short QT intervals were defined as 320 ms (very short) and 340 ms (short). The prevalence of QT interval <320 ms based on ...
  56. [56]
    Short QT Syndrome: From Bench to Bedside - PMC - NIH
    Viskin et al also reported shorter than normal QT interval (QTc <360 ms in males and <370 ms in females) in patients with idiopathic ventricular fibrillation.
  57. [57]
    Short QT Syndrome - Symptoms, Causes, Treatment | NORD
    SQTS can cause dangerous heart rhythms including atrial fibrillation, ventricular tachycardia and ventricular fibrillation. These can occur suddenly, sometimes ...
  58. [58]
    Short QT Syndrome - ECG Library Diagnosis - LITFL
    ECG features · Short QT interval · Lack of normal changes in QT interval with heart rate · Peaked T waves, particularly in precordial leads · Short, or absent, ST ...
  59. [59]
    Differences in twelve-lead electrocardiogram between symptomatic ...
    In addition to the short QT interval, the ST segment is almost absent and the T waves are tall and peaked. Only a few cases of this syndrome have been reported ...
  60. [60]
    Short QT syndrome: The current evidences of diagnosis and ...
    Oct 6, 2020 · SQTS patients have a short or even absent ST segment, with the T wave starting immediately after the S wave. T wave is usually narrower and ...
  61. [61]
    Identifying risk of cardiac events in short QT syndrome - Heart Rhythm
    In the mentioned European Short QT Registry, atrial fibrillation or atrial flutter was observed in 15% of the population.
  62. [62]
  63. [63]
    Impact of prolonged and short QT intervals on immediate risks ... - NIH
    Sep 12, 2025 · Primary outcomes were 3-month risks of new-onset atrial fibrillation (AF) or ventricular arrhythmia (VA), with secondary focus on 3-month ...
  64. [64]
    Impact of prolonged and short QT intervals on immediate risks
    Sep 12, 2025 · Several studies reported that QTc prolongation has been linked to unfavorable cardiovascular outcomes, including arrhythmias, sudden death, and ...
  65. [65]
    Long QT Syndrome Overview - GeneReviews® - NCBI Bookshelf
    Feb 20, 2003 · Pathogenic variants in KCNH2, KCNQ1, and SCN5A account for 90% of individuals with an identified molecular cause of LQTS. Three clinical ...
  66. [66]
    CONGENITAL LONG QT SYNDROME: A SYSTEMATIC REVIEW - NIH
    Mutations in minor LQTS genes account for 5% of congenital LQTS, whereas about 20% of all patients will have established clinical diagnosis of LQTS but without ...
  67. [67]
    Congenital Short QT Syndrome - PMC - NIH
    In both cases the ECG showed a markedly short QT interval (QTc 280 ms), suggesting that short QT may be responsible for electrical instability and ...Congenital Short Qt Syndrome · Genetics · Diagnosis
  68. [68]
    Andersen-Tawil Syndrome - GeneReviews® - NCBI Bookshelf
    Nov 22, 2004 · A KCNJ2 pathogenic missense variant was identified in a female age five years and her father who had short QT intervals and asymmetric T waves ...
  69. [69]
  70. [70]
    Drug-induced QT interval prolongation: mechanisms and clinical ...
    This review focuses on the mechanism of drug-induced QT prolongation, risk factors for TdP, culprit drugs, prevention and monitoring of prolonged drug-induced ...
  71. [71]
    Mechanisms of drug induced QT interval prolongation - PubMed
    There are two well described mechanisms: blocking of the ion channel cavity of HERG; or causing an abnormal protein trafficking required for the location of ...
  72. [72]
    Managing drug-induced QT prolongation in clinical practice - NIH
    Normal QTc intervals are typically <450 ms for men and <460 ms for women. For every 10 ms increase, there is a ~5% increase in the risk of arrhythmic events.
  73. [73]
    Crediblemeds: Home
    August 2024 Changes to the QTdrugs List and List of Drugs to Avoid in cLQTS ... Copyright: The CredibleMeds® website is intended for personal and professional use ...QTDrugs Lists · For Healthcare Providers · Members Login · For EveryoneMissing: categories 2023
  74. [74]
    April 2024 Changes to the QTdrugs List and List of Drugs to Avoid in ...
    Apr 29, 2024 · Therefore, Ivabradine has been changed to the Known Risk of TdP category. In addition, Quizartinib (leukemia therapy) was added to the Known ...Missing: 2023 | Show results with:2023
  75. [75]
    Changes to the QTdrugs List and List of Drugs to Avoid in CLQTS
    Dec 2, 2024 · Opipramol (antidepressant), Revumenib (anticancer) and Sitafloxacin (antibiotic) are associated with the development of QT prolongation but lack convincing ...Missing: 2023 | Show results with:2023
  76. [76]
    Drug-Induced Long QT Syndrome - PMC - PubMed Central
    Accumulation of large series of cases of drug-induced TdP has allowed these ... 1–3% incidence with QT-prolonging drugs. High drug concentrations and ...
  77. [77]
    The real-world incidence of severe QT prolongation in patients ...
    Jan 14, 2024 · Drug-induced torsades de pointes have a reported annual incidence in studies of hospital admissions of 4 cases per 100,000 person-years. 5.
  78. [78]
    A literature-based algorithm for the assessment, management, and ...
    Dec 24, 2018 · The literature-based algorithm developed provides a stepped-based approach for the assessment, monitoring, and management of drug-induced QTc prolongation in ...
  79. [79]
    QTNet: Predicting Drug-Induced QT Prolongation With Artificial ...
    May 1, 2024 · An ECG-based CNN can accurately predict diLQTS in the outpatient setting while maintaining its predictive performance over time.
  80. [80]
    Aborted Sudden Cardiac Death Due to Acquired QT Prolongation
    Feb 4, 2025 · Other significant causes of acquired QT prolongation include acute myocardial ischemia, electrolyte disturbances (hypokalemia, hypomagnesemia, ...Missing: pathologies | Show results with:pathologies
  81. [81]
    QT interval prolongation in patients with acute ischemic stroke
    QT interval prolongation is common in patients with stroke and increases the risk of malignant arrhythmia and sudden death.
  82. [82]
    QTc interval prolongation in critically ill patients: Prevalence, risk ...
    Jun 13, 2018 · Prospective studies in ICUs have shown prevalences of LQTS of 24% [5], 46.6% [9], 27.9% [10], 39% [11], 61% [12] and 52% [13]. Although LQTS is ...
  83. [83]
    QT Prolonging Drugs - StatPearls - NCBI Bookshelf
    It is measured from the Q wave until the T wave, and the QT interval clinically represents the repolarization of the ventricles. Many commonly used medications ...<|control11|><|separator|>
  84. [84]
    Electrocardiographic Manifestations of Calcium Abnormalities - PMC
    Most commonly, the characteristic ECG manifestation of hypocalcemia is prolongation of the QT interval as a result of lengthening of the ST segment.
  85. [85]
    Short QT Syndrome: From Bench to Bedside | Circulation
    Aug 1, 2010 · By definition, secondary causes of short QT interval such as hyperkalemia, acidosis, hypercalcemia, hyperthermia, effects of drugs like ...
  86. [86]
    Abstract 4147160: Hashimoto Thyroiditis and Congenital Long QT ...
    Nov 11, 2024 · Hypothyroidism leads to a prolonged QT interval due to modulation of the potassium channel by low circulating T3, leading to a disproportionate ...
  87. [87]
    The corrected QT (QTc) prolongation in hyperthyroidism and ... - NIH
    A prolonged QTc is related to an increased risk of sudden arrhythmic cardiac mortality. While it is known that hypothyroidism is associated with QTc ...
  88. [88]
    Acquired Long QT Syndrome after Acute Myocardial Infarction
    After an MI occurs, the QTc is minimally prolonged, but typically remains within the normal range. This QTc prolongation often correlates with infarct size and ...
  89. [89]
    QT interval dynamics in patients with ST-elevation MI - PMC - NIH
    QT duration is often prolonged during STEMI; this prolongation is associated with increased mortality and adverse events.
  90. [90]
    Prolongation of QTc interval and risk of stroke - PubMed Central - NIH
    Prolonged QTc interval has been reported in 38–71% of patients during acute stroke, constituting the most frequent single ECG abnormality in this setting (5).
  91. [91]
    Cardiac complications of malnutrition in adolescent patients
    Descriptive studies report prolongation of the corrected QT interval (QTc) in these patients relative to controls, albeit within the normal reference range.
  92. [92]
    Hypothermia - StatPearls - NCBI Bookshelf
    Jan 19, 2024 · Cold temperatures can slow down impulse conduction through potassium channels, prolonging QT intervals. An elevated J point that can produce an ...Missing: starvation | Show results with:starvation
  93. [93]
    High prevalence of corrected QT interval prolongation in acutely ill ...
    Conclusions: We find QT prolongation to be common (24%), with Torsade de Pointes representing 6% of in-hospital cardiac arrests. Predictors of QT prolongation ...
  94. [94]
    QT Interval Prolongation in Chronic Liver Disease - NIH
    Sep 20, 2025 · Non-Alcoholic Fatty Liver Disease (NAFLD), 39 (25) ; Cirrhosis, n (%), 108 (70) ; Non-Cirrhotic CLD, n (%), 47 (30) ; Child-Pugh Class (Cirrhosis ...
  95. [95]
    Association of QTc prolongation with liver function test and ... - NIH
    Jun 30, 2025 · QT prolongation correlates with elevated LFTs and cirrhotic complications. Hence, the need for ECG monitoring in cirrhosis patients to detect ...
  96. [96]
    QTc interval prolongation and its associated factors among HIV ...
    Dec 5, 2024 · QTc interval prolongation, which is linked to cardiac arrhythmia and sudden cardiac death, is common in HIV-infected patients.
  97. [97]
    Prevalence of prolonged QTc interval among HIV infected patients ...
    Sep 26, 2024 · Patients with prolonged QT interval are at increased risk of sudden cardiac death (SCD) and the risk of developing prolonged QT interval ...
  98. [98]
    Torsade de Pointes - Medscape Reference
    May 6, 2024 · Drug-associated torsade de pointes is relatively rare, but is becoming increasingly common; its incidence is as high as 2-3% with certain drugs.Etiology Of Torsade · Acquired Long Qt Syndromes · Treatment Of Torsade
  99. [99]
    Short QT Syndrome: a familial cause of sudden death - PubMed
    The short QT syndrome is characterized by familial sudden death, short refractory periods, and inducible ventricular fibrillation.
  100. [100]
    Short QT Syndrome: A Familial Cause of Sudden Death
    The short QT syndrome is characterized by familial sudden death, short refractory periods, and inducible ventricular fibrillation.
  101. [101]
    Short QT syndrome - PubMed
    Aug 15, 2005 · The short QT syndrome constitutes a new clinical entity that is associated with a high incidence of sudden cardiac death, syncope, and/or atrial fibrillation.
  102. [102]
    Concealed Long QT Syndrome and Intractable Partial Epilepsy
    Torsades de pointes and ventricular fibrillation triggered by LQTS can cause syncope, seizures, or sudden death depending on the duration of the ventricular ...
  103. [103]
    Impact of prolonged and short QT intervals on immediate risks of ...
    Our findings revealed a U-shaped correlation between QTc intervals and the occurrence of AF, VA, and mortality within a 3-month observation ...
  104. [104]
    QT Interval Dynamics and Cardiovascular Outcomes: A Cohort ...
    Sep 28, 2021 · An abnormally prolonged QT interval (>450 ms in men and >460 ms in women) can lead to early afterdepolarizations and premature action potentials ...
  105. [105]
    QT interval and long-term mortality risk in the Framingham Heart Study
    These data confirm that using Bazett's heart rate correction, QTc, overestimates the association with mortality. An association with all-cause mortality ...Missing: prognostic implications
  106. [106]
    QT Interval and Long‐Term Mortality Risk in the Framingham Heart ...
    Aug 13, 2012 · These data confirm that using Bazett's heart rate correction, QTc, overestimates the association with mortality. An association with all-cause ...Missing: implications | Show results with:implications
  107. [107]
    QT interval Independently Predicts Mortality and Heart Failure in ...
    QTc-ER > 445 ms independently predicts clinical events in STEMI, providing incremental prognostic value to established clinical predictors and NT-proBNP.
  108. [108]
    QT prolongation predicts short-term mortality independent of ...
    Apr 8, 2019 · A prolonged corrected QT interval (QTc) ≥500 ms is a powerful predictor of short-term mortality overruling comorbidities. QTc ≥500 ms did also ...
  109. [109]
    Augmented Oscillations in QT Interval Duration Predict Mortality Post ...
    Nov 8, 2020 · Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study.
  110. [110]
    Prolonged QTc interval predicts all-cause mortality in patients with ...
    Oct 3, 2013 · Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden.
  111. [111]
    Inflammation and Heart Rate–corrected QT Interval: Evidence for a ...
    Dec 1, 2018 · Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden.Missing: events | Show results with:events
  112. [112]
    Prediction of Mortality Using Measures of Cardiac Autonomic ...
    Mar 1, 2008 · Diabetic patients with a QTc prolongation >440 ms had a threefold increased risk of mortality. In contrast, increased QT dispersion did not ...
  113. [113]
    Prolonged QTc interval predicts mortality in patients with Type I ...
    Aug 6, 2025 · QTc max. was 442 (1.2) ms (mean (SEM)) for survivors and 457 (3.7) in patients who died (P < 0.001). In a ...
  114. [114]
    Autonomic neuropathy and prolongation of QT interval in human ...
    This study confirms that the QTc measurement is a reliable parameter indicating the presence of autonomic neuropathy. Since QT prolongation may determine ...
  115. [115]
    Increased QT Interval Dispersion Predicts 15-Year Cardiovascular ...
    Feb 10, 2012 · Nevertheless, findings from the current study are consistent with the view that QTd is a better cardiovascular risk predictor than QTc in type 2 ...
  116. [116]
    Prognostic value of QT interval parameters in type 2 diabetes mellitus
    QT interval dispersion seems a better prognostic marker than maximum QT interval, particularly in patients without previous cardiac diseases.
  117. [117]
    Acquired long QT syndrome in chronic kidney disease patients - PMC
    The acquired pathologic conditions that lead to QT prolongation and TdP are complex and diverse. Whereas prescription drugs account for the majority of cases of ...Missing: pathologies hypothyroidism
  118. [118]
    Association of QT interval with mortality by kidney function
    Oct 21, 2017 · Both prolonged QTc and CKD are independently associated with increased risk of mortality. When combined, risk of mortality is higher in those with CKD by eGFR ...
  119. [119]
    How to Diagnose and Manage QT Prolongation in Cancer Patients
    QT prolongation is thought to be caused by downregulation of potassium currents in hypertrophied and failing hearts (7). Other non-cardiac systemic conditions, ...
  120. [120]
    Incidence, Diagnosis, and Management of QT Prolongation Induced ...
    Dec 7, 2017 · QT prolongation has been linked to an increased risk of life‐threatening ventricular arrhythmia and reports of sudden cardiac death (SCD).
  121. [121]
    Differential diagnosis of cardiac arrhythmias in infants with ...
    Aug 6, 2025 · Introduction . Cardiac arrhythmias have not been considered as complications of whooping cough so far. The relevance of the study is ...
  122. [122]
    Treatment of Pertussis | Whooping Cough - CDC
    Oct 27, 2025 · The risk of developing severe pertussis and life-threatening complications outweighs the potential risk of IHPS. ... QT interval.
  123. [123]
    E14 Clinical Evaluation of QT/QTc Interval Prolongation and ... - FDA
    May 31, 2024 · GUIDANCE DOCUMENT. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs October 2005.
  124. [124]
    [PDF] the clinical evaluation of qt/qtc interval prolongation and ... - ICH
    The 'thorough QT/QTc study' would typically be conducted early in clinical development to provide maximum guidance for later trials, although the precise timing ...Missing: 2024 | Show results with:2024
  125. [125]
    E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval ...
    Aug 26, 2022 · This Q&A document is intended to clarify key issues to facilitate implementing the ICH E14 Clinical Evaluation of the QT/QTc Interval ...Missing: 2024 | Show results with:2024
  126. [126]
    FDA's insights: implementing new strategies for evaluating drug ...
    Jun 25, 2025 · Based on QT study reports reviewed by the FDA between 2016 and 2024, changes to the E14 guideline have resulted in a 34% decrease in the ...
  127. [127]
    Scientific white paper on concentration-QTc modeling - PubMed
    This white paper provides recommendations on how to plan and conduct a definitive QTc assessment of a drug using C-QTc modeling in early phase clinical ...
  128. [128]
    Practical guide to concentration-QTc modeling: a hands-on tutorial
    Jul 26, 2025 · Concentration-QTc (C-QTc) analysis is a model-based method widely used to assess the impact of drugs on QT interval duration.
  129. [129]
    An introduction to QT interval prolongation and non-clinical ...
    The box in Figure 3 called 'Additional non-clinical data' encompasses a variety of in vitro and in vivo assays that add to the hERG and in vivo QT data.
  130. [130]
    Translating preclinical safety studies to clinical QT prolongation
    This retrospective study compared hERG block potency with drug-induced QTc prolongation assessed during rigorous thorough QT (TQT) clinical studies.
  131. [131]
    QTNet: Predicting Drug-Induced QT Prolongation With Artificial ...
    May 1, 2024 · An ECG-based CNN can accurately predict diLQTS in the outpatient setting while maintaining its predictive performance over time.
  132. [132]
    Corrected QT Interval (QTc) Diagnostic App for the Oncological ...
    This study aimed to examine whether this approach can be made more efficient and comfortable by a smartphone app (QTc Tracker), supporting single-lead ECG ...
  133. [133]
    Development of an AI-Driven QT Correction Algorithm for Patients in ...
    A CNN model applied to AF ECGs accurately predicted the sinus QTc interval, outperforming current alternatives and exhibiting a high negative predictive value.
  134. [134]
    Drug-Induced QT Prolongation And Torsades de Pointes - PMC - NIH
    Many distinct genetic mutations and polymorphisms lead to congenital long QT syndrome, which occurs in about 0.0005% of live births. ... prolong the QT interval ...